resTORbio, Inc. TORC Income Statement

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17
Operating expenses:
Research and development
69,623	73,634	51,872	36,519	31,811	31,065	33,508	30,076	21,651	16,839	0	0	0
General and administrative
11,523	11,823	10,509	9,733	9,385	8,640	7,360	5,705	4,074	2,043	0	0	0
Total operating expenses
81,146	85,457	62,381	46,252	41,196	39,705	0	0	0	-	-	-	-
Total operating expenses
-	-	-	-	-	-	-	-	-	-	0	0	0
Loss from operations
-81,146	-85,457	-62,381	-46,252	-41,196	-39,705	-40,868	-35,781	-25,725	-18,882	0	0	0
Other income, net
-345	-63	708	608	283	-7	2,123	0	0	-	0	-	0
Loss before income taxes
-78,674	-82,703	-59,549	-43,520	-38,789	-37,588	-54,911	-49,814	-40,280	-33,778	0	0	0
Income tax expense
34	36	0	0	0	-	-	-	-	-	-	-	-
Net loss
-78,708	-82,739	-59,606	-43,565	-38,824	-37,614	-54,911	-49,814	-40,280	-33,778	0	0	0
Net loss per share, basic and diluted
-0.19	-0.84	-0.68	-0.51	-0.38	-0.18	-0.30	-0.48	-0.46	-5.53	-0.75	-0.94	-1.20
Weighted-average common shares used in computing net loss per share, basic and diluted
36,445	36,309	36,217	35,684	29,014	28,140	28,046	28,046	21,523	4,537	4,408	4,302	2,789
Other comprehensive gain (loss):
Net loss
-78,708	-82,739	-59,606	-43,565	-38,824	-37,614	-35,167	-30,817	0	-	0	0	-
Net unrealized (losses) gains on marketable securities
0	90	104	135	0	-	0	0	-	-	-	-	-
Comprehensive loss
-78,708	-82,649	-59,421	-43,365	-38,792	-37,655	-35,243	-30,847	0	-	0	0	-